The global osteoarthritis therapeutics market has been growing steadily, with a revenue estimate of $7.3 billion in 2020 and a projected reach of $11.0 billion by 2025. This growth, at a Compound Annual Growth Rate (CAGR) of 8.7% from 2020 to 2025, is driven by various factors, including a large geriatric and target patient population and improved healthcare infrastructure in several Asia-Pacific (APAC) countries, offering substantial growth opportunities.
Download PDF Brochure-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994
Market Dynamics
Drivers: Rising Government Investments and Pain Medication Adoption
The adoption of pain medications for managing osteoarthritis-related pain is on the rise, driven by their ease of administration and affordability. Medications such as oral analgesics (e.g., acetaminophen and NSAIDs), topical agents, intra-articular agents, and nutraceuticals have shown significant efficacy, with a 30% reduction in chronic pain reported. This high adoption of pain medications is expected to drive market growth.
Restraints: Adverse Cardiovascular Events Linked to NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for osteoarthritis pain relief. However, their use is associated with an increased risk of adverse cardiovascular events. This risk could discourage doctors from prescribing NSAIDs, potentially driving patients towards alternative treatments.
Opportunities: Personalized Medicine
Advancements in diagnosing, treating, and monitoring osteoarthritis have paved the way for personalized medications. Biomarkers that identify patients likely to respond to specific therapies can increase treatment response rates and minimize treatment-related side effects. Personalized approaches can significantly impact osteoarthritis treatment regimens.
Market Segmentation
Knee Osteoarthritis Leads by Anatomy
- Knee osteoarthritis therapeutics is the largest and fastest-growing segment, primarily due to its high incidence.
Viscosupplementation Agents Dominate Drug Type
- Viscosupplementation agents, followed by nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids, account for the largest share in drug types. Viscosupplementation agents effectively relieve osteoarthritis pain through joint injections, offering better lubrication.
Parenteral Route Leads in Administration
- Parenteral administration is the most widely adopted route for osteoarthritis therapeutics due to ease of administration and better pharmacokinetics and pharmacodynamics.
Hospital Pharmacies Hold the Distribution Share
- Hospital pharmacies, followed by online and retail pharmacies, dominate the distribution channel due to the high volume of patients seeking osteoarthritis treatments in hospitals.
Prescription Drugs Dominate Purchasing Patterns
- Prescription drugs, as opposed to over-the-counter drugs, account for a larger share in purchasing patterns, mainly because most osteoarthritis therapeutics require prescriptions.
Regional Insights
Europe Commands the Market
- Europe leads the global osteoarthritis therapeutics market, attributed to rising incidence, a growing geriatric population, increasing obesity rates, and injuries from sports and road accidents.
Key Players
- Key players in the market include Sanofi, Horizon Therapeutics PLC, Johnson & Johnson, GlaxoSmithKline PLC, Bayer AG, Abbott, Pfizer, Inc., Eli Lilly, Anika Therapeutics, Inc., Novartis AG, Ferring Pharmaceuticals, Bioventus, Zimmer Biomet Holdings, Fidia Farmaceutici s.p.a., Flexion Therapeutics, Pharmed Limited, Virchow Biotech, Kitov Pharmaceuticals Ltd., Assertio Therapeutics, Atnahs, Almatica Pharma LLC, OrthogenRx, LABRHA, Hanmi Pharm. Co., Ltd., and Laboratorio Reig Jofre.
Conclusion
The global osteoarthritis therapeutics market is set for substantial growth, driven by increasing adoption of pain medications, advances in personalized medicine, and the rising prevalence of osteoarthritis. While the risk associated with NSAIDs remains a concern, innovations in treatment approaches promise better management of this common joint condition. Europe stands as a significant player in the market, driven by various demographic and health factors. As research and development continue to evolve, the market is expected to witness further expansion and innovation.
